Tag: interleukin-2

St. Jude scientists found that deleting the gene ZMYND8 relieves CD8-positive T-cell exhaustion and synergizes with immunotherapy to improve anti-tumor ...

UChicago Medicine has launched a first-of-its-kind investigator-initiated clinical trial of a fully on-site manufactured T-cell receptor therapy engineered to target ...

Researchers have developed an optimized tumor-infiltrating lymphocyte manufacturing protocol that shows preclinical efficacy against NF1- and schwannomatosis-related nerve sheath tumors, ...

Researchers in Madrid have developed an in vitro stimulation model showing that B cells from patients with common variable immunodeficiency ...

A reanalysis of the MIROCALS trial shows that the TRICALS clinical risk score adds useful prognostic information in ALS but ...

A new review in the Journal of Translational Medicine maps the evidence linking regulatory T cell dysfunction to vasculitis and ...

A preclinical study shows that CAR-T cells engineered to secrete an Fc-fused IL-2(C125S) variant persist longer, retain mitochondrial fitness, and ...

A new review details how interleukin-2 both powers and undermines tumor-infiltrating lymphocyte therapy, and how engineered alternatives may finally break ...

A selective dual T-cell activator directed at the TCR beta chain revives exhausted antitumor T cells and sensitizes checkpoint-resistant cancers ...

A translational modelling study finds that PD-1 receptor occupancy does not predict immune activation during pembrolizumab therapy, challenging current dosing ...